Facing the persistent headwinds of post-pandemic market volatility and Ukraine war-driven inflation, Roquette’s 2024 financial results reveal a substantial decline. The French plant-based excipients giant saw its EBITDA drop by 13% to €529 million (~US$573.6 million) — representing a margin of 11.8% — while turnover decreased by 10% from 2023 to €4.495 million (~US$4.867 million), according to newly released figures. Growth in specialty products, particularly in the company’s Pharma Solutions activities, partially offset the pressure from declining selling prices.
